176 related articles for article (PubMed ID: 38096371)
1. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Bourgeois W; Cutler JA; Aubrey BJ; Wenge DV; Perner F; Martucci C; Henrich JA; Klega K; Nowak RP; Donovan KA; Boileau M; Wen Y; Hatton C; Apazidis AA; Olsen SN; Kirmani N; Pikman Y; Pollard JA; Perry JA; Sperling AS; Ebert BL; McGeehan GM; Crompton BD; Fischer ES; Armstrong SA
Blood; 2024 Apr; 143(15):1513-1527. PubMed ID: 38096371
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
3. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
[TBL] [Abstract][Full Text] [Related]
4. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
Heikamp EB; Henrich JA; Perner F; Wong EM; Hatton C; Wen Y; Barwe SP; Gopalakrishnapillai A; Xu H; Uckelmann HJ; Takao S; Kazansky Y; Pikman Y; McGeehan GM; Kolb EA; Kentsis A; Armstrong SA
Blood; 2022 Feb; 139(6):894-906. PubMed ID: 34582559
[TBL] [Abstract][Full Text] [Related]
5. Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?
Swaminathan M; Bourgeois W; Armstrong SA; Wang ES
Cancer J; 2022 Jan-Feb 01; 28(1):62-66. PubMed ID: 35072375
[TBL] [Abstract][Full Text] [Related]
6. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
7. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
8. Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.
Tubío-Santamaría N; Jayavelu AK; Schnoeder TM; Eifert T; Hsu CJ; Perner F; Zhang Q; Wenge DV; Hansen FM; Kirkpatrick JM; Jyotsana N; Lane SW; von Eyss B; Deshpande AJ; Kühn MWM; Schwaller J; Cammann C; Seifert U; Ebstein F; Krüger E; Hochhaus A; Heuser M; Ori A; Mann M; Armstrong SA; Heidel FH
Mol Cancer; 2023 Dec; 22(1):196. PubMed ID: 38049829
[TBL] [Abstract][Full Text] [Related]
9. IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.
Aubrey BJ; Cutler JA; Bourgeois W; Donovan KA; Gu S; Hatton C; Perlee S; Perner F; Rahnamoun H; Theall ACP; Henrich JA; Zhu Q; Nowak RP; Kim YJ; Parvin S; Cremer A; Olsen SN; Eleuteri NA; Pikman Y; McGeehan GM; Stegmaier K; Letai A; Fischer ES; Liu XS; Armstrong SA
Nat Cancer; 2022 May; 3(5):595-613. PubMed ID: 35534777
[TBL] [Abstract][Full Text] [Related]
10. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers.
Shi Q; Xu M; Kang Z; Zhang M; Luo Y
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
[TBL] [Abstract][Full Text] [Related]
11. Mutant NPM1 Directly Regulates Oncogenic Transcription in Acute Myeloid Leukemia.
Uckelmann HJ; Haarer EL; Takeda R; Wong EM; Hatton C; Marinaccio C; Perner F; Rajput M; Antonissen NJC; Wen Y; Yang L; Brunetti L; Chen CW; Armstrong SA
Cancer Discov; 2023 Mar; 13(3):746-765. PubMed ID: 36455613
[TBL] [Abstract][Full Text] [Related]
12. A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1.
Numata M; Haginoya N; Shiroishi M; Hirata T; Sato-Otsubo A; Yoshikawa K; Takata Y; Nagase R; Kashimoto Y; Suzuki M; Schulte N; Polier G; Kurimoto A; Tomoe Y; Toyota A; Yoneyama T; Imai E; Watanabe K; Hamada T; Kanada R; Watanabe J; Kagoshima Y; Tokumaru E; Murata K; Baba T; Shinozaki T; Ohtsuka M; Goto K; Karibe T; Deguchi T; Gocho Y; Yoshida M; Tomizawa D; Kato M; Tsutsumi S; Kitagawa M; Abe Y
Cancer Cell Int; 2023 Feb; 23(1):36. PubMed ID: 36841758
[TBL] [Abstract][Full Text] [Related]
13. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Fiskus W; Mill CP; Birdwell C; Davis JA; Das K; Boettcher S; Kadia TM; DiNardo CD; Takahashi K; Loghavi S; Soth MJ; Heffernan T; McGeehan GM; Ruan X; Su X; Vakoc CR; Daver N; Bhalla KN
Blood Cancer J; 2023 Apr; 13(1):53. PubMed ID: 37055414
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Effects of the RAR
Fleischmann M; Bechwar J; Voigtländer D; Fischer M; Schnetzke U; Hochhaus A; Scholl S
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610989
[TBL] [Abstract][Full Text] [Related]
15. Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation.
Thomas X
Oncol Ther; 2024 Mar; 12(1):57-72. PubMed ID: 38300432
[TBL] [Abstract][Full Text] [Related]
16. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
17. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia.
Frett B; Stephens KE; Koss B; Melnyk S; Farrar J; Saha D; Roy Choudhury S
Cancer Sci; 2024 Mar; 115(3):963-973. PubMed ID: 38226414
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Lenard A; Xie HM; Pastuer T; Shank T; Libbrecht C; Kingsley M; Riedel SS; Yuan ZF; Zhu N; Neff T; Bernt KM
Exp Hematol; 2020 May; 85():57-69. PubMed ID: 32437908
[TBL] [Abstract][Full Text] [Related]
20. Menin is necessary for long term maintenance of meningioma-1 driven leukemia.
Libbrecht C; Xie HM; Kingsley MC; Haladyna JN; Riedel SS; Alikarami F; Lenard A; McGeehan GM; Ernst P; Bernt KM
Leukemia; 2021 May; 35(5):1405-1417. PubMed ID: 33542482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
